{"entity":{"id":"nct07521605","kind":"trial","name":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer","aka":[],"tldr":"A phase 2 trial of irinotecan (and liposomal irinotecan), capecitabine and camrelizumab in colorectal cancer, run by Guangdong Provincial People's Hospital, not yet recruiting.","summary":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer is a phase 2, interventional study registered as NCT07521605 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 44 participants, started 2026-05-20 and due to reach its primary completion in 2031-12-31. Interventions recorded: Short-Course Radiotherapy; Liposomal Irinotecan (nal-IRI); Capecitabine; Camrelizumab. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete Response Rate. Colorectal eligibility wording from the registry: \"Histologically confirmed diagnosis of rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07521605","url":"https://clinicaltrials.gov/study/NCT07521605"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","topoisomerase-inhibitors"],"targets":[],"drugs":["irinotecan","capecitabine","camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07521605","phase":"2","setting":"Short-Course Radiotherapy Followed by Liposomal Irinotecan, Capecitabine, and Camrelizumab as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Low Rectal Cancer: A Prospective Single-Arm Phase II Trial Protocol","sponsor":"Guangdong Provincial People's Hospital","enrolled":44,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07521605/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}